Actinium Pharmaceuticals Inc. (ATNM) NYSE MKT LLC
$7.06 0.10 (1.44%)
Market Cap: $204.60M
As of 04/24/24 04:00 PM EDT. Market closed.
Actinium Pharmaceuticals Inc. (ATNM)
NYSE MKT LLC
$7.06
0.10 (1.44%)
Market Cap: $204.60M
As of 04/24/24 04:00 PM EDT. Market closed.
Add to Portfolio
actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Sandesh Seth
Full Time Employees
56
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Sandesh Seth
Full Time Employees
56
Address
275 Madison Ave Fl 7, New York, New York, 10016-1101.
PRICE CHART FOR ACTINIUM PHARMACEUTICALS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$7.22
Previous Close
$6.96
Days Range
$6.88 - $7.32
52 week range
$4 - $9.86
Volume
153,433
Avg. Volume (30 days)
387,528
Market Cap
$204.60M
Dividend Yield
-
P/E
-
Shares Outstanding
29,396,411
Open
$7.22
Previous Close
$6.96
Days Range
$6.88 - $7.32
52 week range
$4 - $9.86
Volume
153,433
Avg. Volume (30 days)
387,528
Market Cap
$204.60M
Dividend Yield
-
P/E
-
Shares Outstanding
29,396,411
FINANCIAL STATEMENTS FOR ACTINIUM PHARMACEUTICALS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR ACTINIUM PHARMACEUTICALS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Berger Mark Stanley | Chief Medical Officer | Mar 05, 2019 | Option Exercise | $0.60 | 3,500 | 2,100 | 22,500 | Mar 07, 2019, 04:15 PM |
| SETH SANDESH | Chairman & CEO | Feb 21, 2019 | Option Exercise | $0.60 | 8,125 | 4,875 | 161,458 | Feb 21, 2019, 04:45 PM |
| SETH SANDESH | Chairman & CEO | Dec 10, 2018 | Buy | $0.44 | 10,000 | 4,372 | 153,333 | Dec 10, 2018, 04:14 PM |
| O'Loughlin Steve | Principal Financial Officer | Dec 10, 2018 | Buy | $0.44 | 10,000 | 4,350 | 35,500 | Dec 10, 2018, 04:10 PM |
| Ludwig Dale L. | Chief Scientific Officer | Nov 19, 2018 | Buy | $0.45 | 10,000 | 4,499 | 10,000 | Nov 20, 2018, 05:08 PM |
| SETH SANDESH | CEO | Jul 17, 2018 | Buy | $0.79 | 10,000 | 7,900 | 143,333 | Jul 17, 2018, 05:13 PM |
| O'Loughlin Steve | Principal Financial Officer | Jun 15, 2018 | Buy | $0.50 | 12,000 | 6,000 | 25,500 | Jun 15, 2018, 06:08 PM |
| SETH SANDESH | Chairman & CEO | Apr 19, 2018 | Buy | $0.38 | 5,000 | 1,900 | 133,333 | Apr 20, 2018, 04:15 PM |
| Berger Mark Stanley | Chief Medical Officer | Mar 06, 2018 | Option Exercise | $0.50 | 14,000 | 7,000 | 19,000 | Mar 19, 2018, 05:04 PM |
| SETH SANDESH | Chairman & CEO | Mar 06, 2018 | Option Exercise | $0.50 | 52,500 | 26,250 | 128,333 | Mar 08, 2018, 04:35 PM |
| Ray Nitya G. | Executive VP | Mar 06, 2018 | Option Exercise | $0.50 | 10,000 | 5,000 | 20,000 | Mar 08, 2018, 04:32 PM |
| Steinhart Richard I | Director | Mar 06, 2018 | Option Exercise | $0.50 | 7,000 | 3,500 | 9,500 | Mar 08, 2018, 04:24 PM |
| O'Loughlin Steve | Principal Financial Officer | Mar 06, 2018 | Option Exercise | $0.50 | 10,000 | 5,000 | 13,500 | Mar 08, 2018, 04:20 PM |
| Shetty Ajit | Director | Feb 28, 2018 | Buy | $0.43 | 22,730 | 9,774 | 22,730 | Mar 01, 2018, 07:08 AM |
| SETH SANDESH | Chairman & CEO | Aug 02, 2017 | Buy | $0.75 | 33,333 | 25,000 | 75,833 | Aug 04, 2017, 04:35 PM |
| Ray Nitya G. | Executive Vice President | Aug 02, 2017 | Buy | $0.75 | 10,000 | 7,500 | 10,000 | Aug 04, 2017, 04:22 PM |
| Berger Mark Stanley | Chief Medical Officer | Jun 15, 2017 | Buy | $1.11 | 5,000 | 5,550 | 5,000 | Jun 15, 2017, 04:56 PM |
| SETH SANDESH | Chairman and CEO | Jun 15, 2017 | Buy | $1.16 | 7,500 | 8,725 | 42,500 | Jun 15, 2017, 04:54 PM |
| O'Loughlin Steve | Principal Financial Officer | Jun 15, 2017 | Buy | $1.17 | 3,500 | 4,095 | 3,500 | Jun 15, 2017, 04:51 PM |
| SETH SANDESH | Executive Chairman | Dec 30, 2016 | Buy | $0.88 | 5,000 | 4,400 | 35,000 | Jan 03, 2017, 08:00 AM |
| SETH SANDESH | Executive Chairman | Dec 12, 2016 | Buy | $0.98 | 5,000 | 4,900 | 30,000 | Dec 12, 2016, 04:44 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Aug 31, 2016 | Sale | $1.83 | 136,853 | 251,118 | 4,821,226 | Sep 01, 2016, 05:01 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Aug 30, 2016 | Sale | $1.81 | 56,074 | 101,254 | 4,878,988 | Sep 01, 2016, 05:01 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Aug 29, 2016 | Sale | $1.72 | 25,000 | 42,875 | 4,914,988 | Aug 30, 2016, 05:07 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Aug 26, 2016 | Sale | $1.70 | 25,000 | 42,620 | 4,939,490 | Aug 30, 2016, 05:07 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Aug 15, 2016 | Sale | $1.72 | 4,439 | 7,635 | 4,957,517 | Aug 17, 2016, 04:05 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Aug 16, 2016 | Sale | $1.72 | 5,029 | 8,652 | 4,952,888 | Aug 17, 2016, 04:05 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Jul 12, 2016 | Sale | $1.80 | 3,100 | 5,581 | 4,962,056 | Jul 14, 2016, 04:29 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Jul 11, 2016 | Sale | $1.80 | 800 | 1,440 | 4,965,056 | Jul 12, 2016, 05:11 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Jul 08, 2016 | Sale | $1.80 | 21,190 | 38,142 | 4,965,856 | Jul 12, 2016, 05:11 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Jul 06, 2016 | Sale | $1.80 | 10,500 | 18,900 | 4,987,046 | Jul 07, 2016, 04:24 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Jul 05, 2016 | Sale | $1.82 | 10,340 | 18,862 | 5,001,886 | Jul 07, 2016, 04:24 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Jul 01, 2016 | Sale | $1.81 | 128,950 | 233,897 | 5,091,995 | Jul 05, 2016, 04:36 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Jun 30, 2016 | Sale | $1.80 | 19,150 | 34,539 | 5,140,786 | Jul 05, 2016, 04:36 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Jun 15, 2016 | Sale | $1.90 | 33,619 | 63,876 | 5,155,986 | Jun 17, 2016, 04:35 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Jun 02, 2016 | Sale | $2.01 | 17,790 | 35,716 | 5,196,395 | Jun 06, 2016, 07:20 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Jun 01, 2016 | Sale | $2.09 | 40,114 | 83,838 | 5,242,709 | Jun 02, 2016, 04:21 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | May 31, 2016 | Sale | $1.93 | 129,336 | 249,547 | 5,358,735 | Jun 02, 2016, 04:21 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | May 26, 2016 | Sale | $1.92 | 40,068 | 77,061 | 5,389,745 | May 31, 2016, 06:58 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | May 25, 2016 | Sale | $1.90 | 36,400 | 69,235 | 5,427,313 | May 26, 2016, 05:43 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Apr 26, 2016 | Sale | $1.96 | 6,500 | 12,725 | 5,455,813 | Apr 26, 2016, 05:25 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Apr 25, 2016 | Sale | $2.02 | 18,385 | 37,204 | 5,476,398 | Apr 26, 2016, 05:25 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Apr 22, 2016 | Sale | $2.07 | 27,692 | 57,336 | 5,502,849 | Apr 26, 2016, 05:25 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Apr 19, 2016 | Sale | $2.03 | 150,000 | 304,321 | 5,652,878 | Apr 21, 2016, 04:56 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Apr 21, 2016 | Sale | $2.04 | 13,000 | 26,557 | 5,509,590 | Apr 21, 2016, 04:56 PM |
| Memorial Sloan-Kettering Cancer Center | 10% Owner | Apr 20, 2016 | Sale | $2.03 | 33,497 | 68,042 | 5,551,787 | Apr 21, 2016, 04:56 PM |
| Nicholson, C. David | Director | Apr 14, 2016 | Buy | $2.00 | 5,000 | 10,000 | 15,000 | Apr 18, 2016, 05:28 PM |
| DAVE KAUSHIK J | CEO and Interim CFO | Apr 14, 2016 | Buy | $2.02 | 10,000 | 20,180 | 88,500 | Apr 18, 2016, 05:27 PM |
| SETH SANDESH | Director | Apr 18, 2016 | Buy | $1.98 | 6,500 | 12,885 | 25,000 | Apr 18, 2016, 05:26 PM |
| SETH SANDESH | Director | Apr 15, 2016 | Buy | $2.00 | 3,500 | 7,015 | 18,500 | Apr 18, 2016, 05:26 PM |
| SETH SANDESH | Director | Apr 14, 2016 | Buy | $2.00 | 5,000 | 10,000 | 15,000 | Apr 18, 2016, 05:26 PM |
| Steinhart Richard I | Director | Apr 14, 2016 | Buy | $2.01 | 2,500 | 5,025 | 2,500 | Apr 18, 2016, 05:24 PM |
| TRAVERSA SERGIO | Director | Apr 15, 2016 | Buy | $2.02 | 1,000 | 2,020 | 3,000 | Apr 18, 2016, 05:24 PM |
| TRAVERSA SERGIO | Director | Apr 14, 2016 | Buy | $2.02 | 2,000 | 4,040 | 2,000 | Apr 18, 2016, 05:24 PM |
| DAVE KAUSHIK J | President, CEO and Interim CFO | May 07, 2015 | Option Exercise | $2.45 | 120,501 | 295,227 | 85,583 | May 22, 2015, 05:08 PM |
| DAVE KAUSHIK J | President, CEO and Interim CFO | May 07, 2015 | Option Exercise | $2.45 | 35,583 | 87,178 | 85,583 | May 22, 2015, 05:08 PM |
| CICIC DRAGAN | COO and Chief Medical Officer | May 07, 2015 | Option Exercise | $2.52 | 2,380 | 5,998 | 560 | May 22, 2015, 05:07 PM |
| CICIC DRAGAN | COO and Chief Medical Officer | May 07, 2015 | Option Exercise | $2.52 | 560 | 1,411 | 560 | May 22, 2015, 05:07 PM |
| CICIC DRAGAN | COO and Chief Medical Officer | Feb 21, 2014 | Option Exercise | $5.55 | 3,500 | 19,425 | 3,500 | Mar 16, 2015, 05:26 PM |
| SETH SANDESH | Director | Aug 08, 2013 | Option Exercise | $3.60 | 10,000 | 36,000 | 0 | Dec 24, 2013, 03:43 PM |
| TRAVERSA SERGIO | Interim CFO | Aug 08, 2013 | Option Exercise | $3.60 | 10,000 | 36,000 | 0 | Dec 24, 2013, 03:41 PM |
| MAZANET ROSEMARY | Director | May 15, 2013 | Buy | $3.95 | 100 | 395 | 100 | May 22, 2013, 08:04 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Load More Insider Transactions
FUNDS WITH A POSITION IN ACTINIUM PHARMACEUTICALS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 1,691,914 | 0.00022% | -4.14% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 569,549 | 0.0003% | 5% | Other |
| ROYCE & ASSOCIATES LP | 50,000 | 0.00235% | No change | Value |
CHANGE IN SHARES OUTSTANDING FOR ACTINIUM PHARMACEUTICALS INC
STOCK BUYBACKS FOR ACTINIUM PHARMACEUTICALS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
1.37%
1Q
06/30/2023
4.62%
2Q
03/31/2023
6.74%
3Q
12/31/2022
7.59%
4Q
09/30/2022
9.00%
5Q
06/30/2022
15.58%
6Q
03/31/2022
23.86%
7Q
12/31/2021
24.15%
8Q
09/30/2021
27.34%
9Q
06/30/2021
35.57%
10Q
03/31/2021
49.27%
11Q
09/30/2020
77.73%
13Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR ACTINIUM PHARMACEUTICALS INC
LOADING...